Erratum

Abstract

BJU InternationalVolume 95, Issue 9 p. 1385-1386 Free Access Erratum First published: 12 May 2005 https://doi.org/10.1111/j.1464-410X.2005.05600.xAboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In [1], the following error was published on page 582. RESULTS, FIRST PARAGRAPH, THIRD SENTENCE Overall, most patients in each treatment group had concomitant diseases, most commonly: hypertension, darifenacin 78/268 (29%), placebo 42/127 (33%); allergic rhinitis, 58/268 (22%) and 19/127 (15%); and oesophagitis, 37/268 (14%) and nine/127 (15%), respectively. The text was incorrect and should have read: RESULTS, FIRST PARAGRAPH, THIRD SENTENCE Overall, most patients in each treatment group had concomitant diseases, most commonly: hypertension, darifenacin 78/268 (29%), placebo 42/127 (33%); allergic rhinitis, 58/268 (22%) and 19/127 (15%); and oesophagitis, 37/268 (14%) and 19/127 (15%), respectively. The following error was published on page 585. TABLE 4 Table 4. Summary of most frequently reported AEs according to dose escalation AEs, n (%) Increased dose No increased dose 2 weeks 12 weeks 2 weeks 12 weeks N 108 108 160 160 Constipation 20 (18.5) 24 (22.2) 10 (6.3)† 32 (20.0) Dry mouth 19 (17.6) 22 (20.4) 12 (7.5)* 28 (17.5) Headache 4 (3.7) 5 (4.6) 7 (4.4) 13 (8.1) * P < 0.05, † P < 0.01, two-sided Fisher's exact test comparing incidence rates between the dose-escalation groups during the same period. The text was incorrect and should have read: TABLE 4 Table 4. Summary of most frequently reported AEs according to dose escalation AEs, n (%) No increased dose Increased dose 2 weeks 12 weeks 2 weeks 12 weeks N 108 108 160 160 Constipation 20 (18.5) 24 (22.2) 10 (6.3)† 32 (20.0) Dry mouth 19 (17.6) 22 (20.4) 12 (7.5)* 28 (17.5) Headache 4 (3.7) 5 (4.6) 7 (4.4) 13 (8.1) * P < 0.05, † P < 0.01, two-sided Fisher's exact test comparing incidence rates between the dose-escalation groups during the same period. We apologize for this error Figures 2 and 3 were removed from the manuscript during the Technical Editing of the paper. At the request of the author, these Figures are reproduced overleaf. FIG. 2. Median percentage change from baseline in the number of incontinence episodes per week during treatment with either darifenacin or placebo. *P < 0.05 vs placebo. FIG. 3. Median percent change from baseline in the number of incontinence episodes per week at weeks 2 (red) and 12 (green), according to dose-escalation status (darifenacin-treated patients only). REFERNCE 1 Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005; 95: 580– 6DOI: 10.1111/j.1464-410X.2005.05343.x Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume95, Issue9June 2005Pages 1385-1386 ReferencesRelatedInformation